Navigation Links
Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
Date:9/13/2011

FORT WORTH, Texas, Sept. 13, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming UBS Global Life Sciences Conference. The presentation is scheduled for the opening day of the conference, Monday, September 19th, at 3 pm (EDT) at the Grand Hyatt in New York City.

The presentation will include updates on the Company's ongoing commercial operations, its recent acquisition of Regranex® Gel and Phase 2b summary results for its cell therapy pipeline candidate for venous leg ulcers (HP802-247).

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is presently centered around next-generation cell-based therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® Gel. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.

HEALTHPOINT, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademar
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Healthpoint Biotherapeutics Acquires Regranex® Gel
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... RESEARCH TRIANGLE PARK, N.C. , June 1, ... FENCF), announced the presentation of positive interim results ... in SIOPEL6: A multi-centre open label randomised phase ... (STS) in reducing ototoxicity in patients receiving cisplatin ... data was presented at the American Society of ...
(Date:6/1/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that it ... commercial food testing laboratory based in southwest India ... a base for the company,s new operations in ... was incorporated in 1990, and its business has grown ... quality testing for major hotels and restaurants in its home ...
(Date:6/1/2015)... 01, 2015 Sistemic Ltd. and ... into a commercial collaboration agreement and signed a ... their technologies and work together towards advancing the ... RoosterBio and Sistemic will collaborate on utilizing microRNA ... more precise and relevant characterization panels for hMSC ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Neogen acquires India food safety company 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... for Combining Efficiency and Renewables into an Energy ... recognized as an important component to America' energy ... discussion about including Energy Efficiency into what many ... Standards (RPS) . The whole idea being that ...
... saw around business computing that you should improve processes before ... the business side could just get its act together and ... And if your only objective is to automate what youre ... leaves a lot of technology value on the table and ...
... been awarded the maximum $250,000 grant from the ... program for its enzyme research. The grant program is ... high potential value. , ,Under the program, NSF matched ... outside investors. , ,The award will speed commercialization of ...
Cached Biology Technology:Energy efficiency is no longer the Rodney Dangerfield of energy 2Energy efficiency is no longer the Rodney Dangerfield of energy 3Innovate, Automate, or Improve? You Don't Have to Choose. 2Innovate, Automate, or Improve? You Don't Have to Choose. 3
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... athletes looking to boost performance comes in the form of ... for its popularity is twofold says Scott Forbes, a doctoral ... for nitric oxide that is known to improve blood flow, ... to working muscles and assist with metabolic waste product removal. ...
... Bethesda, MD The Association for Molecular Pathology ... to exclusively license the subject matter of a cancer-related ... written remarks were submitted to NIH in response to ... entitled, "Prospective Grant of Exclusive License: The Development of ...
... of engineering principles to understand and treat medical conditions ... damage to the brain caused by a traumatic injury. ... presented in a special issue of Journal of ... Liebert, Inc. ( http://www.liebertpub.com ) The entire issue is ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3AMP opposes exclusive licensing of NIH proteomics patent 2Bioengineering yields new approaches for diagnosing and treating traumatic brain injury 2
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Mouse BLC/BCA 1 - 10kDa...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Biology Products: